Prominent examples include olaparib (AZD2281), rucaparib (AGO14699), niraparib (MK4827), veliparib (ABT888), and talazoparib (BMN673) (Figure 6).[16] In 2015, olaparib (Lynparza®) and rucaparib (Rubraca®) have passed phase III clinical trials and are FDA‐approved for the treatment of advanced ovarian cancer patients with mutations in the germline BRCA1/2 genes.[91] Niraparib (Zejula®) was additionally approved for the maintenance treatment of recurrent and platinum‐sensitive ovarian cancer patients. This evidence concerns the gene BRCA1 and ovarian carcinoma.